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Abstract
Background: The rising level of antimicrobial resistance among bacterial pathogens is one of the most significant
public health problems globally. While the antibiotic resistance of clinically important bacteria is closely tracked in
many developed countries, the types and levels of resistance and multidrug resistance (MDR) among pathogens
currently circulating in most countries of sub-Saharan Africa are virtually unknown.
Methods: From December 2013 to April 2014, we collected 93 urine specimens from all outpatients showing symptoms
of urinary tract infection (UTI) and 189 fomite swabs from a small hospital in Bo, Sierra Leone. Culture on chromogenic
agar combined with biochemical and DNA sequence-based assays was used to detect and identify the bacterial isolates.
Their antimicrobial susceptibilities were determined using a panel of 11 antibiotics or antibiotic combinations.
Results: The 70 Enterobacteriaceae urine isolates were identified as Citrobacter freundii (n = 22), Klebsiella pneumoniae
(n = 15), Enterobacter cloacae (n = 15), Escherichia coli (n = 13), Enterobacter sp./Leclercia sp. (n = 4) and Escherichia
hermannii (n = 1). Antimicrobial susceptibility testing demonstrated that 85.7 % of these isolates were MDR while 64.3 %
produced an extended-spectrum ß-lactamase (ESBL). The most notable observations included widespread resistance
to sulphonamides (91.4 %), chloramphenicol (72.9 %), gentamycin (72.9 %), ampicillin with sulbactam (51.4 %) and
ciprofloxacin (47.1 %) with C. freundii exhibiting the highest and E. coli the lowest prevalence of multidrug resistance.
The environmental cultures resulted in only five Enterobacteriaceae isolates out of 189 collected with lower overall
antibiotic resistance.
Conclusions: The surprisingly high proportion of C. freundii found in urine of patients with suspected UTI supports
earlier findings of the growing role of this pathogen in UTIs in low-resource countries. The isolates of all analyzed
species showed worryingly high levels of resistance to both first- and second-line antibiotics as well as a high
frequency of MDR and ESBL phenotypes, which likely resulted from the lack of consistent antibiotic stewardship
policies in Sierra Leone. Analysis of hospital environmental isolates however suggested that fomites in this naturally
ventilated hospital were not a major reservoir for Enterobacteriaceae or antibiotic resistance determinants.
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Background
The increasing rate of antibiotic resistance among bacterial
pathogens causing both hospital- and community-acquired
infections is a serious threat to public health world-
wide [1, 2]. Trends among pathogens belonging to
the Enterobacteriaceae are especially troubling consider-
ing their ubiquity in the environment and animal hosts
and the relative ease with which they acquire and transfer
genetic determinants that confer resistance to most classes
of antibiotics. Recently, this phenomenon has resulted in
the emergence and international spread of bacteria caus-
ing a number of deadly hospital outbreaks [3, 4]. These
include increasingly abundant and problematic bacterial
strains harboring extended-spectrum ß-lactamases (ESBL)
that confer resistance to the majority of ß-lactam
antibiotics and carbapenemases that confer resistance
to carbapenem compounds, the most powerful and
last line of ß-lactam antibiotics [5–9]. Typically,
ESBL-producing strains, carbapenem resistant Entero-
bacteriaceae (CRE), and other multidrug resistant
(MDR) Enterobacteriaceae possess several additional
resistance mechanisms to other classes of popular an-
tibiotics such as phenicols, sulfonamides, fluoroquino-
lones, tetracyclines, and aminoglycosides [10, 11].
This makes them extremely difficult – and in some
cases, virtually impossible – to treat.
While MDR bacterial pathogens have been vigorously
investigated in countries with mandated antibiotic
stewardship policies and adequate resources, scant data
are available from developing countries [12]. As a
salient example, a recent survey of the antimicrobial
susceptibility of Enterobacteriaceae that caused urinary
tract infections (UTI) in Africa revealed that <200
studies were published between the years 2000 and
2012. Furthermore, although these analyses originated
from 14 African countries, 90 % of the analyzed isolates
came from South Africa and only a handful of the
studies were conducted in other sub-Saharan African
countries [13]. This kind of data is critical for deve-
loping viable antibiotic use policies and therapeutic
strategies, especially since these same antimicrobial
compounds are available without prescription in many
developing countries (often resulting in widespread
misuse [14–16]) and the situation can be further con-
founded by the presence of counterfeit or substandard
quality drugs [17, 18]. To date, no official data on anti-
microbial resistance of Enterobacteriaceae circulating
in Sierra Leone are available [12]. To begin to gain
some insight into the antibiotic sensitivity of Enterobac-
teriaceae in this area, we conducted a prospective study
at Mercy Hospital (Bo, Sierra Leone) using bacterial
isolates obtained from urine of patients with symptoms
consistent with UTI and the samples collected from the
surrounding hospital environment.
Methods
Bacterial isolates from clinical and hospital environmental
samples
Mercy Hospital is a small private hospital in Bo, Sierra
Leone, that refers about 2000 patients per year to its
own clinical laboratory for testing [19]. Clinical samples
for this study were obtained between December 12th
2013 and January 27th 2014 from all outpatients show-
ing symptoms of UTI and referred for urine culture by
the attending clinician. The samples originated from
patients ranging in age from 1 to 59 with 63.4 % of the
patients being female.
A total of 93 urine samples were screened on CHRO-
Magar Orientation medium (CHROMagar, Paris, France).
Seventy isolates were obtained from samples originating
from 59 patients with significant bacteriuria (some
samples yielded more than one isolate due to mixed infec-
tions). They included 57 isolates producing colonies with
a dark blue color after overnight incubation at 37 °C
(a phenotype characteristic of Klebsiella, Enterobacter,
Citrobacter and Serratia when grown on this medium).
Although this study was designed with the overall goal to
analyze the antimicrobial resistance patterns of the non-
E. coli Enterobacteriaceae, given the accepted role of
Escherichia coli as the most prevalent bacterial pathogen
causing UTI, 13 isolates producing dark pink to reddish
colonies (the E. coli phenotype on this medium) were also
added to the study.
Environmental isolates were obtained from 189 swab
samples collected in and around the hospital between
January 12th, 2014 and April 29th, 2014. The swabbing
was performed using sterile cotton swabs moistened
with sterile saline. Surfaces of approximately 10 cm2 of
the tested area were swabbed and the swab was then
swept across a CHROMagar Orientation medium plate
which was subsequently incubated overnight at 37 °C.
The areas swabbed included outpatient waiting areas,
general and maternity wards, and waiting areas and
benches in the diagnostic lab located in a separate build-
ing (Additional file 1: Table S1).
Isolate identification
All collected Enterobacteriaceae isolates were identified
to the species level using the API 20E identification sys-
tem (bioMérieux, Marcy-l′Etoile, France) and 16S rRNA
and rpoB gene sequencing. For the 16S rRNA-based
identification, a fragment of 16S rDNA that spanned the
V3 and V4 variable regions was PCR amplified and
sequenced [20]. Genus- (or family-) level identification
was determined using the naïve Bayesian classifier avail-
able through the Ribosomal Database Project (release
11) (http://rdp.cme.msu.edu/classifier/classifier.jsp), with
80 % confidence as the identification threshold [21].
Identification based on rpoB gene sequencing was
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performed using previously published primers [22, 23],
with a BLAST search performed on the obtained ampli-
con DNA sequence. The highest-ranking BLAST result
with the highest coverage was used as the basis for
organism identification. A final consensus identification
was based on a combination of the three identification
methods (Table 1). In instances where the methods did
not result in concordant identifications, a genus-level
identification was assigned to the isolate based on the
agreement of two of the methods. The species identifica-
tion determined by rpoB gene sequencing was used
when the phenotypic identification method and rpoB
sequencing results were discordant. Clinical isolates for
which API 20E-based identification was ambiguous
(SL108, SL116, SL122, SL124, SL127) or for which the
three identification methods gave discordant results
(SL184, SL191, SL201 and SL204) were subjected to
additional identification using the ID 32 rapid system
(bioMérieux). Twenty-six of the non-Enterobacteriaceae
environmental isolates were identified to the genus level
only using 16S rRNA gene sequencing.
Antibiotic susceptibility testing and ESBL detection
Every clinical and environmental isolate included in this
study was assayed by disk diffusion for susceptibility to
the following antibiotics or antibiotic combinations:
ampicillin with sulbactam (SAM), aztreonam (ATM),
ceftazidime (CAZ), chloramphenicol (C), ciprofloxacin
(CIP), doxycycline (D), gentamicin (GM), imipenem
(IMP), kanamycin (K), sulfisoxazole (G), and tigecycline
(TGC). The susceptibility testing was conducted using
BBL Mueller Hinton II Agar (MHA medium, Becton
Dickinson, Franklin Lakes, NJ) according to Clinical and
Laboratory Standards Institute (CLSI) recommendations
[24]. CLSI interpretative criteria were applied for classifi-
cation of the isolates into susceptible, intermediate and
resistant categories [24]. In the case of tigecycline, for
which there are no CLSI criteria, FDA recommended
breakpoints were used [25]. Minimum inhibitory con-
centrations (MIC) for imipenem were determined using
imipenem E-test strips (bioMérieux) according to manu-
facturer’s recommendations. The ESBL phenotype was
determined using cefotaxime/cefotaxime + clavulanic
acid (CT/CTL) and ceftazidime/ceftazidime + clavulanic
acid (TZ/TZL) E-test strips (bioMérieux) according to
manufacturer’s recommendations or by the disk diffusion
method using disks containing cefotaxime/cefotaxime +
clavulanic acid and ceftazidime/ceftazidime + clavulanic
acid according to CLSI recommendations [24]. E. coli ref-
erence strain ATCC 25922, susceptible to all 11 antibiotics
tested in this study, was used for quality control purposes.
The MDR phenotype was defined as the demonstrated
resistance to at least three antibiotics belonging to
different classes of antimicrobial compounds.
PCR-based detection of blaCTX-M
All of the isolates were tested for the presence of genes
encoding CTX-M type ESBLs using universal CTX-M
primers as previously described [26].
Results
Identification of isolates from urine cultures
Out of the 93 urine samples tested, 57 generated dark
(metallic) blue colonies after an overnight incubation on
CHROMagar Orientation medium, which was indicative
of non-E. coli Enterobacteriaceae. These isolates were
subcultured on MHA medium and identified using a
combination of biochemical and molecular techniques.
The consensus identification results for the clinical
Enterobacteriaceae isolates are presented in Table 1 and
the complete identification results are available in
Additional file 2: Table S2. The consensus identification
results revealed that the largest number of non-E. coli
Enterobacteriaceae isolates were Citrobacter freundii
(n = 22), followed by Enterobacter cloacae and Klebsiella
pneumoniae (n = 15 isolates each) and Escherichia her-
mannii (n = 1). We were not able to identify unequivocally
the genus of four non-E. coli Enterobacteriaceae isolates
(SL184, SL191, SL201 and SL204) due to divergent pheno-
type identification results and ambiguous results of 16S
rRNA and rpoB sequence based analysis. The sequence-
based identification indicated that these four isolates
belong to a non-E. cloacae species of Enterobacter or to
Leclercia sp. (data not shown). This group of four isolates
is therefore referred to as “Enterobacter sp./Leclercia sp.”
All 13 isolates producing dark pink to reddish colonies
included in the study were confirmed as E. coli.
Enterobacteriaceae in the hospital environment
To explore the role of fomites as reservoirs or agents in
the transmission of MDR Enterobacteriaceae, hospital
surfaces were also examined via swab and culture. An
initial set of 95 samples, collected between January 12th
and 15th, 2014, resulted in 30 isolates producing dark
blue colonies on CHROMagar Orientation medium.
However, subsequent subculture, biochemical analyses,
and 16S rRNA gene sequencing revealed that only four
of these 30 isolates belonged to the Enterobacteriaceae.
The remaining isolates were identified as Bacillus sp.
(n = 23) and Staphylococcus sp. (n = 3), Additional file 2:
Table S2. The analysis of an additional set of 94 hospital
environmental samples, collected between March 31st
and April 29th, 2014, yielded only one additional Entero-
bacteriaceae isolate, totaling only five Enterobacteriaceae
isolates among the 189 environmental samples analyzed
(2.7 %). Species-level identifications of these five isolates
revealed two K. pneumoniae, two E. cloacae and one
Pantoea dispersa.
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Table 1 Antibiotic sensitivity testing results
ID Identificationa Disk diffusionb E-test ESBLc
ATM CAZ CIP IMP TGC C D G GM K SAM IMP Phenotype CTX-M
Clinical isolates
SL122 Citrobacter freundii R R R S S R R R R R R 0.250 YES YES
SL124 R I R S S R R R R R R 0.380 YES YES
SL127 R I R S I R R R R R R 0.380 YES YES
SL129 S I R S I R R R R I R 0.190 N/D NO
SL150 R R R S I I R R R R R 0.190 YES YES
SL151 R I R S S R R R R I R 0.380 YES YES
SL153 R R R I I R R R R I R 0.250 YES YES
SL154 R R R I S R R R R I R 0.190 N/D NO
SL155 R R R S S R R R R I R 0.250 N/D NO
SL156 R R R I I R I R R R R 0.250 YES YES
SL157 R R R S I R I R R R R 0.250 YES YES
SL170 R I R S S R R R R I R 0.750 YES YES
SL172 R R R S S S R R R R I 0.190 YES YES
SL173 R R R I S R R R R I R 0.380 YES YES
SL177 R R R S S R R R R I R 0.250 YES YES
SL187 R I R S S S I R R I I 0.250 YES YES
SL193 R I R S S R I R R S R 0.250 YES YES
SL194 R R R S S R R R R I R 0.380 N/D NO
SL197 R R R S S S I R R I I 0.250 YES YES
SL200 R R R S I S R R R R R 0.190 YES YES
SL202 R R R S I S R R R R R 0.190 YES YES
SL205 R R R I I S R R R R I 0.190 YES YES
SL160 Enterobacter cloacae S S S S S S S R S S S 0.380 NO NO
SL161 R R I I I R S R R R R 0.250 YES YES
SL167 I I I S S R I R R I R 0.380 YES YES
SL168 R R I I S R I R R I R 2.000 YES YES
SL174 R I I S S R I R R R I 0.380 YES YES
SL175 I I S S S R S R R R R 0.250 YES YES
SL179 R R R S S R I R R R R 0.250 YES YES
SL181 S S S S S R S R R I I 0.380 YES YES
SL182 R R I I S R S R R I R 0.380 YES YES
SL189 S S I S S R S R R I I 0.250 YES YES
SL192 S S I S S R R R R S S 0.380 NO NO
SL195 I I S S S R S R R I I 0.380 YES YES
SL198 R R S S S R S R R I R 0.250 YES YES
SL199 R I I S S R S R R I I 0.380 YES YES
SL203 I I I S S R S R R I I 0.380 YES YES
SL115 Escherichia coli S S S S S S S S S S S 0.190 NO NO
SL121 S S R S S R R R S S I 0.190 NO NO
SL125 S S S S S S S S S S S 0.190 NO NO
SL133 S S S S S S R R S S R 0.190 NO NO
SL137 S S S S S S R R S S R 0.190 NO NO
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Urine isolate antibiotic susceptibility
The 70 urine isolates were tested for their susceptibility
to 11 antibiotics or antibiotic combinations covering six
classes of antimicrobial compounds and an ESBL pheno-
type (Table 1). Overall, 85.7 % of the clinical isolates
were identified as MDR. More than 90 % of the urinary
isolates were resistant to sulphonamides. Large propor-
tions of the isolates were also found to be resistant to
gentamycin (72.9 %), chloramphenicol (72.9 %), ampicil-
lin/sulbactam (51.4 %), and/or ciprofloxacin (47.1 %). A
considerable proportion of the clinical isolates (38.6 %)
also demonstrated high resistance to the third gener-
ation cephalosporin, ceftazidime, which is typically indi-
cative of ESBL production but may be due to inducible
AmpC enzymes common in C. freundii and Enterobacter
spp. Indeed, testing for the presence of ESBLs revealed
Table 1 Antibiotic sensitivity testing results (Continued)
SL152 S S I S S R R R R S S 0.190 NO NO
SL158 S S R I S R R R S S R 0.190 NO NO
SL159 S S S I S S S S S S S 0.190 NO NO
SL169 S S S S S R R R S S S 0.250 NO NO
SL171 S S S S S R I R S S R 0.250 NO NO
SL176 S S R S S S S R S S I 0.250 NO NO
SL178 R S S S S R I R I S S 0.250 NO NO
SL188 S S S S S R I R S S S 0.250 NO NO
SL166 Escherichia hermannii R R I S S R S R R I R 0.190 YES YES
SL108 Klebsiella pneumoniae S S I S S S S S S S S 0.250 NO NO
SL113 S S I S S R I R R R S 0.250 YES YES
SL116 S S I S S S S S S S S 0.190 NO NO
SL136 S S S S S R S R S S S 0.250 NO NO
SL141 S S S S S S S S S S S 0.250 NO NO
SL162 R R R I I R R R R I R 0.190 YES YES
SL163 R R I I I R R R R S R 0.190 YES YES
SL164 S S I S S R R R R S R 0.190 YES YES
SL165 I I I S S R R R R I R 0.250 YES YES
SL180 S S S S S R S R R I I 0.380 YES YES
SL183 S S S S S R R R S S I 0.250 NO NO
SL185 I I R S S S I R R R I 0.190 YES YES
SL186 I I I S S R R R R S R 0.250 YES YES
SL190 S S R I I R R R S R R 0.250 NO NO
SL196 R R R I I S I R R R I 0.250 YES YES
SL184 Enterobacter sp./Leclercia sp. I I R S S R S R R I I 0.250 YES YES
SL191 I R R I I R S R R I I 0.250 YES YES
SL201 R R R R I R S R R R I 0.250 YES YES
SL204 R R I R I R R R R R I 0.190 YES YES
Environmental isolates
SL512 Enterobacter cloacae S S S I S S R R S S S 0.250 NO NO
SL532 I I S S S R S R R R R N/A YES YES
SL513 Klebsiella pneumoniae R R S S S S S R R I R 0.190 YES YES
SL531 S S S S S S S S S S S 0.190 NO NO
SL522 Pantoea dispersa S S S S S S S S S S S 0.250 NO NO
aConsensus identification based on combination phenotypic (API20E/ID32E) and 16S rRNA and rpoB gene sequencing
bDisk diffusion testing using the following antibiotics: ATM aztreonam, CAZ ceftazidime, CIP ciprofloxacin, IMP imipenem, TGC tigecycline, C chloramphenicol,
D doxycycline, G sulfisoxazole, GM gentamicin, K kanamycin, SAM ampicillin/sulbactam. R resistant, I intermediate, and S sensitive phenotypes were determined
based on CLSI criteria
cESBL phenotypes: YES – ESBL detected, NO – no ESBL present, N/D – ESBL presence could not be determined based on the E-test or double disk diffusion assay
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that 64.3 % of the urine isolates produced an ESBL as
defined by CLSI criteria. PCR-based detection of blaCTX-M
genes in every isolate presenting an ESBL phenotype
(results not shown) confirmed the widespread presence of
these genes and potentially enzymes in the analyzed
isolate collection. In spite of the overall non-susceptibility
to the majority of antimicrobials tested, none of the strains
were resistant to tigecycline, and only two strains were
resistant to imipenem. However, the two strains resistant
to imipenem by disk diffusion – as well as all classified as
having intermediate sensitivity - were deemed susceptible
by CLSI standards when MICs were determined by E-test.
There appeared to be substantial species-specific
differences in antimicrobial resistance with C. freundii
being the most highly MDR species followed by Entero-
bacter sp./Leclercia sp., E. hermannii, E. cloacae, K.
pneumoniae and E. coli (Table 2). All of the C. freundii
urine isolates were resistant to sulfisoxazole, gentamycin
and ciprofloxacin and most were resistant to several
other antibiotics: the average C. freundii isolate was re-
sistant to >7 antibiotics out of the 11 tested. In addition,
81.8 % of the C. freundii isolates produced ESBLs. The
presence or absence of ESBLs in four isolates (SL129,
SL154, SL155 and SL194) could not be determined
based on phenotype only. Double disk synergy tests
indicated the possible presence of an inhibitor-resistant ß-
lactamase in these strains (data not shown).
Fourteen of the 15 E. cloacae isolates (93.3 %) were
MDR, with 13 producing an ESBL and showing resistance
for sulfisoxazole and a diminished sensitivity to at least
five other antibiotics (with chloramphenicol, gentamycin,
and kanamycin being among the most prevalent). The
majority of K. pneumoniae isolates (73.3 %) were also
MDR; most were insensitive to at least five antibiotics in-
cluding chloramphenicol, doxycycline, gentamicin and a
combination of ampicillin with sulbactam. Over half ex-
hibited an ESBL phenotype, but a significant proportion
(26.7 %) were sensitive to ciprofloxacin. All four Entero-
bacter sp./Leclercia sp. strains that were isolated from the
urine cultures were positive for ESBL production and
non-susceptible to eight or more antibiotics. One strain
tested resistant or intermediate to all 11 antibiotics tested
by disk diffusion. However, imipenem resistance and
intermediate resistance in these isolates were not con-
firmed by E-test. The single E. hermannii identified among
the urinary isolates presented a phenotype similar to the
Table 2 Percent prevalence of antimicrobial sensitivity phenotypes in urine isolates as determined by the disk diffusion method
Species No. Phenotype Antibiotica ESBL
ATM CAZ CIP IMP TGC C D G GM K SAM
Citrobacter freundii 22 R 95.5 68.2 100.0 0.0 0.0 68.2 77.3 100.0 100.0 45.5 81.8 81.8
I 0.0 31.8 0.0 22.7 40.9 4.5 22.7 0.0 0.0 50.0 18.2
S 4.5 0.0 0.0 77.3 59.1 27.3 0.0 0.0 0.0 4.5 0.0
Enterobacter sp./Leclercia sp. 4 R 50.0 75.0 75.0 50.0 0.0 100.0 25.0 100.0 100.0 50.0 0.0 100.0
I 50.0 25.0 25.0 25.0 75.0 0.0 0.0 0.0 0.0 50.0 100.0
S 0.0 0.0 0.0 25.0 25.0 0.0 75.0 0.0 0.0 0.0 0.0
Escherichia hermannii 1 R 100.0 100.0 0.0 0.0 0.0 100.0 0.0 100.0 100.0 0.0 100.0 100.0
I 0.0 0.0 100.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0 0.0
S 0.0 0.0 0.0 100.0 100.0 0.0 100.0 0.0 0.0 0.0 0.0
Enterobacter cloacae 15 R 46.7 33.3 6.7 0.0 0.0 93.3 6.7 100.0 93.3 26.7 46.7 86.7
I 26.7 40.0 60.0 20.0 6.7 0.0 26.7 0.0 0.0 60.0 40.0
S 26.7 26.7 33.3 80.0 93.3 6.7 66.7 0.0 6.7 13.3 13.3
Klebsiella pneumoniae 15 R 20.0 20.0 26.7 0.0 0.0 66.7 46.7 80.0 60.0 26.7 40.0 60.0
I 20.0 20.0 46.7 26.7 26.7 0.0 20.0 0.0 0.0 20.0 26.7
S 60.0 60.0 26.7 73.3 73.3 33.3 33.3 20.0 40.0 53.3 33.3
Escherichia coli 13 R 7.7 0.0 23.1 0.0 0.0 53.8 46.2 76.9 7.7 0.0 30.8 0.0
I 0.0 0.0 7.7 15.4 0.0 0.0 23.1 0.0 7.7 0.0 15.4
S 92.3 100.0 69.2 84.6 100.0 46.2 30.8 23.1 84.6 100.0 53.8
Overall 70 R 50.0 38.6 47.1 2.9 0.0 72.9 45.7 91.4 72.9 28.6 51.4 62.9
I 12.9 24.3 27.1 21.4 24.3 1.4 21.4 0.0 1.4 37.1 28.6
S 37.1 37.1 25.7 75.7 75.7 25.7 32.9 8.6 25.7 34.3 20.0
aDisk diffusion testing using the following antibiotics: ATM aztreonam, CAZ ceftazidime, CIP ciprofloxacin, IMP imipenem, TGC tigecycline, C chloramphenicol,
D doxycycline, G sulfisoxazole, GM gentamicin, K kanamycin, SAM ampicillin/sulbactam. R resistant, I intermediate, and S sensitive phenotypes were determined
based on CLSI criteria
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Enterobacter sp./Leclercia sp.: it exhibited ESBL produc-
tion and resistance or intermediate resistance to all of the
tested antibiotics with the exception of doxycycline, imipe-
nem and tigecycline. Surprisingly, the E. coli strains were
found to be the least resistant of all of the urine isolates
tested and did not demonstrate the ESBL phenotype.
Nevertheless, 61.5 % of the E. coli isolates could be classi-
fied as MDR and were most commonly resistant to sulfi-
soxazole, chloramphenicol and doxycycline.
Hospital environment isolate antibiotic susceptibility
The same panel of 11 antibiotics were used for suscepti-
bility testing of the five Enterobacteriaceae and 26 non-
Enterobacteriaceae isolates from hospital fomites
(Table 1). Two of the five Enterobacteriaceae isolates
(K. pneumoniae SL513 and E. cloacae SL532) were
MDR and carried ESBLs (Table 1). Of the three other
Enterobacteriaceae isolates, E. cloacae SL512 was re-
sistant to only sulfisoxazole and doxycycline and was
sensitive to all of the other antibiotics tested. The
remaining two isolates, K. pneumoniae SL531 and
Pantoea dispersa SL552, were sensitive to all of the
antibiotics tested.
Breakpoint thresholds have been published for
Staphylococcus spp. for only seven of the 11 antibiotics
used for susceptibility testing and for none of the 11
antibiotics used for testing Bacillus spp. For this reason,
only the zone diameters of the 26 non-Enterobacteriaceae
isolates identified as Staphylococcus spp. and Bacillus spp.
are shown in Additional file 3: Table S3. Of the seven
antibiotics for which Staphylococcus sp. breakpoints have
been published, the tested Staphylococcus isolates were all
deemed susceptible.
Discussion
E. coli typically account for ~80 % of the bacteria isolated
from uncomplicated UTI urines, with non-E. coli
Enterobacteriaceae (e.g., Klebsiella spp., Enterococcus
spp., Citrobacter spp.) usually present at much lower levels
[27, 28]. This study was specifically designed to analyze
the resistance patterns of non-E. coli Enterobacteriaceae.
While we did not determine the overall prevalence of E.
coli in the cultured urine samples, we collected all non-
E. coli Enterobacteriaceae and were surprised to find
that they were present in such a large proportion of the
tested samples (57.0 %). Indeed, both K. pneumoniae
and E. cloacae were cultured from 16.1 % of the urine
samples - levels more typical of complicated UTIs or dia-
betic patients than general outpatient populations [28, 29].
It was particularly unexpected that C. freundii was isolated
from almost a quarter (23.6 %) of the collected urine
samples, accounting for 38.6 % of all non-E.coli isolates.
While surprising, our findings are in agreement with a
number of recent studies that have reported on the
increased incidence of Citrobacter among urinary patho-
gens in developing countries [30–32], thus suggesting that
Citrobacter may be becoming an increasingly important
emerging urinary tract pathogen in resource-limited
settings [33]. The high percentage of the non-E. coli UTI-
associated bacteria analyzed in this study may also indicate
weakened immune systems or additional health problems
in the studied population. However, it is important to bear
in mind that due to the relatively short duration of the
study and small size of the sample, the observed propor-
tions of pathogens recovered from urine samples may not
be representative for the wider population of Bo and not
be typical over longer periods of time.
Overall, data on antibiotic resistance in the Enterobac-
teriaceae from countries in West Africa (with the great
majority originating from Nigeria and Senegal) are
scarce and show enormous variation depending on the
particular population and study design [12, 34]. For
example, the prevalence of the ESBL phenotype in
Enterobacteriaceae have been reported to vary from
10 % in diarrheal samples in Senegal to 96 % in Mali
[34]. With respect to Sierra Leone however, there is an
almost complete lack of information on bacterial anti-
biotic resistance.
The analysis of urine isolates used in this study sug-
gests that clinically relevant MDR bacteria are prevalent
in the studied outpatient population. Especially concern-
ing is the high percentage of ESBL carriage among the
analyzed non-E. coli Enterobacteriaceae, confirmed by
both phenotypic and molecular assays. The chemothera-
peutic options for the treatment of infections caused by
these currently circulating Enterobacteriaceae strains are
limited. Especially worrisome is the fact that a large
proportion of these strains were not only resistant to
first-line antibiotics such as sulphonamides (trimetho-
prim-sulfonamide is among the most commonly used
treatments for uncomplicated UTIs [35]), ß-lactams and
chloramphenicol, but many of them were also resistant
to such second-line drugs as aminoglycosides and broad
spectrum antibiotics such as the fluoroquinolone cipro-
floxacin. While the high percentage of MDR isolates
observed in this collection may be partly explained by
the study design and overrepresentation of species rich
in intrinsic resistance mechanisms (e.g. Citrobacter sp.,
Enterobacter sp.), even the usually less multiresistant
species such as E. coli were found to contain significant
proportion of MDR strains. On the other hand, despite
earlier reports describing the detection of carbapene-
mase (i.e., blaVIM-1, blaDIM-1, blaOXA-51 and blaOXA-58)
and tigecycline (tet(X)) resistance genes in this commu-
nity [14, 36], there was no evidence for the spread of
phenotypic resistance to these last-line antibiotics.
The contamination of the hospital surfaces is usually
considered in the context of increased risk for hospital
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acquired UTIs and spread between inpatients or health-
care workers and patients. Mercy Hospital serves mostly
the needs of an outpatient population (30–50 patients
per day) with a limited number of inpatients (24 beds
with varying occupancy). Many outpatients who spend
considerable amounts of time in waiting rooms and
other areas of the hospital, are exposed to hospital fomi-
tes and have contact with staff serving both outpatient
and inpatient populations. This study made an attempt
to determine the role of hospital environment fomites in
the spread of MDR Enterobacteriaceae in Mercy Hos-
pital. Previous studies have shown that bacterial patho-
gens, including members of Enterobacteriaceae such as
E. coli and K. pneumoniae, are capable of surviving from
days to over a year on dry, inanimate surfaces [37, 38].
Screening the environmental samples collected at Mercy
Hospital demonstrated that the majority of isolates pro-
ducing dark blue colonies on the chromogenic
medium were Bacillus sp. Only five of the isolates
collected from hospital surfaces (2.7 %) were identi-
fied as members of the Enterobacteriaceae. These re-
sults suggest that fomites in the Mercy Hospital open
air ventilated environment are not a major source of
pathogenic Enterobacteriaceae and that the observed
resistance among the outpatient urinary isolates was
likely not acquired from hospital fomite reservoirs.
However, while relatively rare in the hospital environ-
ment, some of these environmental isolates demon-
strated MDR phenotype and carried ESBLs. These
observations warrant vigilance and the implementa-
tion of hospital hygiene procedures to maintain low
levels of fomite contamination and potentially prevent
the wider spread of these MDR pathogens.
Conclusions
The surprisingly high incidence of Citrobacter found
among urine isolates in the analyzed Mercy Hospital
outpatient population suggests that Citrobacter may be
becoming an increasingly important emerging urinary
tract pathogen in this particular resource-limited setting.
The high percentage of other non-E. coli Enterobacteria-
ceae among pathogens found in the urine of these
patients may also indicate the prevalence of additional
health problems in the studied population. Antibiotic
susceptibility testing results show that clinically relevant
MDR Enterobacteriaceae are prevalent in the studied
population, which may reflect the lack of the national
antibiotic stewardship policies in Sierra Leone and wide-
spread access to antimicrobials without prescription.
The results of hospital environment sampling showing
very low level of contamination with MDR Enterobacte-
riaceae suggest that fomites are not a likely source of
these pathogens in Mercy Hospital.
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